{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:41:15Z","timestamp":1795045275403,"version":"4.10.2"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.biopha.2024.117283","type":"journal-article","created":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T09:14:32Z","timestamp":1723367672000},"page":"117283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Therapeutic potential of rifaximin in liver diseases"],"prefix":"10.1016","volume":"178","author":[{"given":"Wanting","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoyue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0380-7999","authenticated-orcid":false,"given":"Chao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biopha.2024.117283_bib1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1021\/jm00145a020","article-title":"4-Deoxypyrido[1\u2032,2\u2032:1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption","volume":"28","author":"Marchi","year":"1985","journal-title":"J. Med Chem."},{"issue":"9","key":"10.1016\/j.biopha.2024.117283_bib2","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1128\/AAC.00161-10","article-title":"Bile acids improve the antimicrobial effect of rifaximin","volume":"54","author":"Darkoh","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2024.117283_bib3","first-page":"159","article-title":"Profile of rifaximin and its potential in the treatment of irritable bowel syndrome","volume":"8","author":"Iorio","year":"2015","journal-title":"Clin. Exp. Gastroenterol."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.117283_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/apt.13406","article-title":"Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases","volume":"43","author":"DuPont","year":"2016","journal-title":"Aliment Pharm. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003495-199549030-00009","article-title":"Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria","volume":"49","author":"Gillis","year":"1995","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF01982198","article-title":"In vitro activity of rifaximin against Helicobacter pylori","volume":"13","author":"M\u00e9graud","year":"1994","journal-title":"Eur. J. Clin. Microbiol Infect. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2024.117283_bib7","first-page":"483","article-title":"In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp","volume":"13","author":"Ripa","year":"1987","journal-title":"Drugs Exp. Clin. Res"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.117283_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000081991","article-title":"Rifaximin: in vitro and in vivo antibacterial activity--a review","volume":"51","author":"Jiang","year":"2005","journal-title":"Chemotherapy"},{"issue":"8","key":"10.1016\/j.biopha.2024.117283_bib9","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","article-title":"In vitro activity and fecal concentration of rifaximin after oral administration","volume":"44","author":"Jiang","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib10","first-page":"1","article-title":"Pharmacokinetics of L\/105, a new rifamycin, in rats and dogs, after oral administration","volume":"29","author":"Venturini","year":"1983","journal-title":"Chemotherapy"},{"issue":"6","key":"10.1016\/j.biopha.2024.117283_bib11","first-page":"373","article-title":"Rifaximin (L\/105), a new topical intestinal antibiotic: pharmacokinetic study after single oral administration of 3H-rifaximin to rats","volume":"3","author":"Cellai","year":"1984","journal-title":"Chemioterapia"},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib12","first-page":"51","article-title":"Pharmacokinetic study of rifaximin after oral administration in healthy volunteers","volume":"14","author":"Descombe","year":"1994","journal-title":"Int J. Clin. Pharm. Res"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.117283_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000081988","article-title":"The pathogenesis of gastrointestinal bacterial overgrowth","volume":"51","author":"Husebye","year":"2005","journal-title":"Chemotherapy"},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00042737-200301000-00012","article-title":"Assessment of orocaecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy","volume":"15","author":"Tursi","year":"2003","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117283_bib15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","article-title":"Modulation of the fecal bile acid profile by gut microbiota in cirrhosis","volume":"58","author":"Kakiyama","year":"2013","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117283_bib16","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/14740338.2016.1186639","article-title":"Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation","volume":"15","author":"Ponziani","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"25","key":"10.1016\/j.biopha.2024.117283_bib17","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.3748\/wjg.v23.i25.4491","article-title":"Eubiotic properties of rifaximin: disruption of the traditional concepts in gut microbiota modulation","volume":"23","author":"Ponziani","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117283_bib18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000068362","article-title":"Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis","volume":"66","author":"Fiorucci","year":"2002","journal-title":"Digestion"},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/jgh.13841","article-title":"Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota","volume":"33","author":"Jin","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib20","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1128\/AAC.00691-09","article-title":"Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles","volume":"54","author":"Brown","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.biopha.2024.117283_bib21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41429-017-0022-y","article-title":"Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses","volume":"71","author":"Dogan","year":"2018","journal-title":"J. Antibiot"},{"issue":"6","key":"10.1016\/j.biopha.2024.117283_bib22","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.4269\/ajtmh.2006.74.1060","article-title":"A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea","volume":"74","author":"Taylor","year":"2006","journal-title":"Am. J. Trop. Med Hyg."},{"issue":"16","key":"10.1016\/j.biopha.2024.117283_bib23","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.2174\/13816128113199990578","article-title":"TRH\/TRH-R1 receptor signaling in the brain medulla as a pathway of vagally mediated gut responses during the cephalic phase","volume":"20","author":"Tach\u00e9","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12868-022-00694-z","article-title":"Rifaximin modulates TRH and TRH-like peptide expression throughout the brain and peripheral tissues of male rats","volume":"23","author":"Pekary","year":"2022","journal-title":"BMC Neurosci."},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41391-018-0041-1","article-title":"The microbiome in prostate inflammation and prostate cancer","volume":"21","author":"Porter","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"6564","key":"10.1016\/j.biopha.2024.117283_bib26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.abl7070","article-title":"Gut bacteria enable prostate cancer growth","volume":"374","author":"McCulloch","year":"2021","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.biopha.2024.117283_bib27","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11011-014-9507-6","article-title":"Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis","volume":"29","author":"Ahluwalia","year":"2014","journal-title":"Metab. Brain Dis."},{"issue":"4","key":"10.1016\/j.biopha.2024.117283_bib28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1027314419843","article-title":"Rifamycins inhibit human neutrophil functions: new derivatives with potential antiinflammatory activity","volume":"21","author":"Spisani","year":"1997","journal-title":"Inflammation"},{"issue":"5","key":"10.1016\/j.biopha.2024.117283_bib29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1023\/A:1022341909396","article-title":"3-(Carboxyalkylthio) rifamycin S and SV derivatives inhibit human neutrophil functions","volume":"22","author":"Spisani","year":"1998","journal-title":"Inflammation"},{"issue":"6","key":"10.1016\/j.biopha.2024.117283_bib30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/030006059702500601","article-title":"Twenty years of experience with intra-articular rifamycin for chronic arthritides","volume":"25","author":"Caruso","year":"1997","journal-title":"J. Int Med Res"},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/030006059202000209","article-title":"Clinical improvement in ankylosing spondylitis with rifamycin SV infiltrations of peripheral joints","volume":"20","author":"Caruso","year":"1992","journal-title":"J. Int Med Res"},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/jpet.110.170225","article-title":"Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation","volume":"335","author":"Cheng","year":"2010","journal-title":"J. Pharm. Exp. Ther."},{"issue":"11","key":"10.1016\/j.biopha.2024.117283_bib33","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bcp.2010.08.022","article-title":"Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells","volume":"80","author":"Mencarelli","year":"2010","journal-title":"Biochem Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib34","first-page":"226","article-title":"Susceptibility to rifaximin and other antimicrobials of bacteria isolated in patients with acute gastrointestinal infections in Southeast Mexico","volume":"82","author":"Novoa-Farias","year":"2017","journal-title":"Rev. Gastroenterol. Mex."},{"issue":"7","key":"10.1016\/j.biopha.2024.117283_bib35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut-liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/apt.14397","article-title":"Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease","volume":"47","author":"Woodhouse","year":"2018","journal-title":"Aliment Pharm. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib37","doi-asserted-by":"crossref","first-page":"G168","DOI":"10.1152\/ajpgi.00190.2011","article-title":"Linkage of gut microbiome with cognition in hepatic encephalopathy","volume":"302","author":"Bajaj","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117283_bib38","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/hep.23917","article-title":"The role of intestinal endotoxin in liver injury: a long and evolving history","volume":"52","author":"Nolan","year":"2010","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.biopha.2024.117283_bib39","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/MEG.0b013e32834a75dc","article-title":"Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt","volume":"23","author":"Trebicka","year":"2011","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib40","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/0016-5085(95)90027-6","article-title":"Antibiotics prevent liver injury in rats following long-term exposure to ethanol","volume":"108","author":"Adachi","year":"1995","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.biopha.2024.117283_bib41","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/hep.1840190529","article-title":"Lipopolysaccharide-neutralizing antibody reduces hepatocyte injury from acute hepatotoxin administration","volume":"19","author":"Czaja","year":"1994","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.biopha.2024.117283_bib42","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1365-2036.2009.03958.x","article-title":"Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis","volume":"29","author":"Vlachogiannakos","year":"2009","journal-title":"Aliment Pharm. Ther."},{"issue":"11","key":"10.1016\/j.biopha.2024.117283_bib43","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/1751-2980.12294","article-title":"Does low-dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study","volume":"16","author":"Zeng","year":"2015","journal-title":"J. Dig. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12072-020-10117-y","article-title":"Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis","volume":"15","author":"Zeng","year":"2021","journal-title":"Hepatol. Int"},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib45","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jhep.2021.09.010","article-title":"Rifaximin-\u03b1 reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial","volume":"76","author":"Patel","year":"2022","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117283_bib46","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jhep.2013.01.038","article-title":"Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function","volume":"58","author":"Du Plessis","year":"2013","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117283_bib47","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1499-3872(16)60135-2","article-title":"Molecular pathogenesis and clinical consequences of iron overload in liver cirrhosis","volume":"15","author":"Sikorska","year":"2016","journal-title":"Hepatobiliary Pancreat. Dis. Int"},{"key":"10.1016\/j.biopha.2024.117283_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.116845","article-title":"Therapeutic potential and mechanisms of Rifaximin in ameliorating iron overload-induced ferroptosis and liver fibrosis in vivo and in vitro","volume":"484","author":"Yuan","year":"2024","journal-title":"Toxicol. Appl. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2024.117283_bib49","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S2468-1253(23)00010-9","article-title":"Rifaximin-\u03b1 for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"Israelsen","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1590-8658(01)80134-1","article-title":"Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study","volume":"33","author":"Borzio","year":"2001","journal-title":"Dig. Liver Dis."},{"issue":"5","key":"10.1016\/j.biopha.2024.117283_bib51","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.25532","article-title":"Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study","volume":"55","author":"Fern\u00e1ndez","year":"2012","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2024.117283_bib52","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1053\/j.gastro.2010.06.019","article-title":"Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis","volume":"139","author":"Arvaniti","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2024.117283_bib53","first-page":"1232","article-title":"Spontaneous bacterial peritonitis--in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998","volume":"96","author":"Thuluvath","year":"2001","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib54","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0168-8278(05)80280-6","article-title":"A prospective study of bacterial infections in patients with cirrhosis","volume":"18","author":"Caly","year":"1993","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib55","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1086\/600291","article-title":"A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia","volume":"49","author":"Falguera","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2024.117283_bib56","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/hep.28330","article-title":"Antibiotic prophylaxis in cirrhosis: good and bad","volume":"63","author":"Fern\u00e1ndez","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib57","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ajg.2009.615","article-title":"Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective","volume":"105","author":"Bajaj","year":"2010","journal-title":"Am. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117283_bib58","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2014.01.024","article-title":"Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013","volume":"60","author":"Jalan","year":"2014","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.biopha.2024.117283_bib59","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/MEG.0000000000000724","article-title":"Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis","volume":"28","author":"Elfert","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib60","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12072-015-9688-z","article-title":"Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study","volume":"10","author":"Assem","year":"2016","journal-title":"Hepatol. Int"},{"issue":"7","key":"10.1016\/j.biopha.2024.117283_bib61","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","article-title":"Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites","volume":"10","author":"Kalambokis","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117283_bib62","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2009.07.058","article-title":"Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis","volume":"137","author":"Zapater","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.117283_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-017-9827-9","article-title":"The portal hypertension syndrome: etiology, classification, relevance, and animal models","volume":"12","author":"Bosch","year":"2018","journal-title":"Hepatol. Int"},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib64","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jhep.2018.04.026","article-title":"The relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis","volume":"69","author":"Alvarado","year":"2018","journal-title":"J. Hepatol."},{"issue":"2 Suppl 1","key":"10.1016\/j.biopha.2024.117283_bib65","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1002\/hep.20993","article-title":"The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule","volume":"43","author":"Iwakiri","year":"2006","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2024.117283_bib66","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib67","article-title":"Beta-blockers in cirrhosis: evidence-based indications and limitations","volume":"2","author":"Rodrigues","year":"2020","journal-title":"JHEP Rep."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.117283_bib68","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jhep.2021.01.018","article-title":"New clinical and pathophysiological perspectives defining the trajectory of cirrhosis","volume":"75","author":"Jalan","year":"2021","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib69","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jhep.2020.11.048","article-title":"The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis","volume":"74","author":"Arroyo","year":"2021","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/liv.12021","article-title":"Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications","volume":"33","author":"Bellot","year":"2013","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib71","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4254\/wjh.v7.i3.425","article-title":"Gut-liver axis in liver cirrhosis: how to manage leaky gut and endotoxemia","volume":"7","author":"Fukui","year":"2015","journal-title":"World J. Hepatol."},{"issue":"45","key":"10.1016\/j.biopha.2024.117283_bib72","doi-asserted-by":"crossref","first-page":"16795","DOI":"10.3748\/wjg.v20.i45.16795","article-title":"Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis","volume":"20","author":"Giannelli","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00042737-200501000-00006","article-title":"Bacterial translocation and its consequences in patients with cirrhosis","volume":"17","author":"Guarner","year":"2005","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib74","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jgh.12070","article-title":"Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis","volume":"28","author":"Vlachogiannakos","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.biopha.2024.117283_bib75","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1007\/s10620-016-4313-0","article-title":"Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis","volume":"61","author":"Dong","year":"2016","journal-title":"Dig. Dis. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2024.117283_bib76","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/apt.14275","article-title":"Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy","volume":"46","author":"Kang","year":"2017","journal-title":"Aliment Pharm. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2024.117283_bib77","doi-asserted-by":"crossref","first-page":"702","DOI":"10.5009\/gnl16478","article-title":"Rifaximin and propranolol combination therapy is more effective than propranolol monotherapy for the reduction of portal pressure: an open randomized controlled pilot study","volume":"11","author":"Lim","year":"2017","journal-title":"Gut Liver"},{"issue":"11","key":"10.1016\/j.biopha.2024.117283_bib78","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2006.08.007","article-title":"Natural history of patients hospitalized for management of cirrhotic ascites","volume":"4","author":"Planas","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib79","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/jhep.2003.50315","article-title":"The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club","volume":"38","author":"Moore","year":"2003","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.biopha.2024.117283_bib80","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/MEG.0000000000000743","article-title":"Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival","volume":"28","author":"Hanafy","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.biopha.2024.117283_bib81","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1172\/JCI7458","article-title":"Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility","volume":"104","author":"Wiest","year":"1999","journal-title":"J. Clin. Invest"},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib82","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3748\/wjg.v26.i2.199","article-title":"Rifaximin improves survival in cirrhotic patients with refractory ascites: a real-world study","volume":"26","author":"Lv","year":"2020","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib83","first-page":"203","article-title":"Hospital mortality in cirrhotic patients at a tertiary care center","volume":"82","author":"Zubieta-Rodr\u00edguez","year":"2017","journal-title":"Rev. Gastroenterol. Mex."},{"key":"10.1016\/j.biopha.2024.117283_bib84","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818800307","article-title":"Rifaximin has the potential to prevent complications of cirrhosis","volume":"11","author":"Flamm","year":"2018","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"34","key":"10.1016\/j.biopha.2024.117283_bib85","doi-asserted-by":"crossref","first-page":"12182","DOI":"10.3748\/wjg.v20.i34.12182","article-title":"Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review","volume":"20","author":"Arab","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib86","first-page":"69","article-title":"The Mexican consensus on nonalcoholic fatty liver disease","volume":"84","author":"Bernal-Reyes","year":"2019","journal-title":"Rev. Gastroenterol. Mex."},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib87","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dld.2014.09.020","article-title":"Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig. Liver Dis."},{"issue":"5","key":"10.1016\/j.biopha.2024.117283_bib88","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib89","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5152\/tjg.2014.7886","article-title":"Role of gut microbiota: obesity and NAFLD","volume":"25","author":"Gangarapu","year":"2014","journal-title":"Turk. J. Gastroenterol."},{"issue":"31","key":"10.1016\/j.biopha.2024.117283_bib90","doi-asserted-by":"crossref","first-page":"11070","DOI":"10.1073\/pnas.0504978102","article-title":"Obesity alters gut microbial ecology","volume":"102","author":"Ley","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.biopha.2024.117283_bib91","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2337\/db06-1491","article-title":"Metabolic endotoxemia initiates obesity and insulin resistance","volume":"56","author":"Cani","year":"2007","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.biopha.2024.117283_bib92","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.tips.2012.03.003","article-title":"Pregnane X receptor as a target for treatment of inflammatory bowel disorders","volume":"33","author":"Cheng","year":"2012","journal-title":"Trends Pharm. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2024.117283_bib93","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2217\/14622416.9.11.1695","article-title":"PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics","volume":"9","author":"Zhang","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/j.biopha.2024.117283_bib94","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/MEG.0000000000001232","article-title":"Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot","volume":"30","author":"Abdel-Razik","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117283_bib95","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/MEG.0000000000000348","article-title":"Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease","volume":"27","author":"Gangarapu","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"15","key":"10.1016\/j.biopha.2024.117283_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155589","article-title":"Effective combination therapy of angiotensin-II receptor blocker and rifaximin for hepatic fibrosis in rat model of nonalcoholic steatohepatitis","volume":"21","author":"Fujinaga","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib97","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0041-1723752","article-title":"Gut-liver axis in nonalcoholic fatty liver disease: the impact of the metagenome, end products, and the epithelial and vascular barriers","volume":"41","author":"Gil-G\u00f3mez","year":"2021","journal-title":"Semin Liver Dis."},{"key":"10.1016\/j.biopha.2024.117283_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.841132","article-title":"Rifaximin ameliorates non-alcoholic steatohepatitis in mice through regulating gut microbiome-related bile acids","volume":"13","author":"Jian","year":"2022","journal-title":"Front Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib99","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/toxsci\/kfs211","article-title":"Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice","volume":"129","author":"Cheng","year":"2012","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/hepr.12904","article-title":"Rifaximin in non-alcoholic steatohepatitis: an open-label pilot study","volume":"48","author":"Cobbold","year":"2018","journal-title":"Hepatol. Res"},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib101","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/j.2040-4603.2013.tb00510.x","article-title":"Kupffer cells in the liver","volume":"3","author":"Dixon","year":"2013","journal-title":"Compr. Physiol."},{"issue":"9","key":"10.1016\/j.biopha.2024.117283_bib102","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrgastro.2013.140","article-title":"Liver disease: Kupffer cells regulate the progression of ALD and NAFLD","volume":"10","author":"Smith","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117283_bib103","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1189\/jlb.6A0114-004RR","article-title":"Chronic alcohol ingestion modulates hepatic macrophage populations and functions in mice","volume":"96","author":"Wang","year":"2014","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib104","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1152\/ajpgi.00384.2001","article-title":"Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines","volume":"282","author":"Diehl","year":"2002","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jemt.1060140305","article-title":"Fine structure and function of Kupffer cells","volume":"14","author":"McCuskey","year":"1990","journal-title":"J. Electron Microsc. Tech."},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib106","first-page":"113","article-title":"Current management of alcoholic hepatitis and future therapies","volume":"4","author":"Saberi","year":"2016","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib107","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-0036-1571297","article-title":"Therapeutic strategies for the treatment of alcoholic hepatitis","volume":"36","author":"Singal","year":"2016","journal-title":"Semin Liver Dis."},{"issue":"12","key":"10.1016\/j.biopha.2024.117283_bib108","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nri1733","article-title":"Monocyte and macrophage heterogeneity","volume":"5","author":"Gordon","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2024.117283_bib109","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2741\/2692","article-title":"Macrophage activation and polarization","volume":"13","author":"Martinez","year":"2008","journal-title":"Front Biosci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib111","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1478-3231.2011.02650.x","article-title":"Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia","volume":"32","author":"Kalambokis","year":"2012","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264278","article-title":"The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: a randomized clinical trial","volume":"17","author":"Kimer","year":"2022","journal-title":"PLoS One"},{"issue":"1-2","key":"10.1016\/j.biopha.2024.117283_bib113","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejphar.2011.06.058","article-title":"Inhibition of NF-\u03baB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells","volume":"668","author":"Mencarelli","year":"2011","journal-title":"Eur. J. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2024.117283_bib114","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1124\/jpet.114.215913","article-title":"Activation of intestinal human pregnane X receptor protects against azoxymethane\/dextran sulfate sodium-induced colon cancer","volume":"351","author":"Cheng","year":"2014","journal-title":"J. Pharm. Exp. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2024.117283_bib115","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1039\/C7RA09689E","article-title":"Rifaximin, a pregnane X receptor (PXR) activator regulates apoptosis in a murine model of breast cancer","volume":"8","author":"Gautam","year":"2018","journal-title":"RSC Adv."},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib116","article-title":"Reduction in gastrointestinal cancers in cirrhotic patients receiving rifaximin vs lactulose only therapy for hepatic encephalopathy","volume":"15","author":"Patel","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib117","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3748\/wjg.v29.i1.61","article-title":"Evolution of care in cirrhosis: preventing hepatic decompensation through pharmacotherapy","volume":"29","author":"Lee","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib118","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1586\/egh.12.80","article-title":"Primary sclerosing cholangitis: a review and update on therapeutic developments","volume":"7","author":"Tabibian","year":"2013","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib119","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-2006-933560","article-title":"Primary sclerosing cholangitis: epidemiology, natural history, and prognosis","volume":"26","author":"Levy","year":"2006","journal-title":"Semin Liver Dis."},{"issue":"5","key":"10.1016\/j.biopha.2024.117283_bib120","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2741\/e490","article-title":"Primary sclerosing cholangitis: etiopathogenesis and clinical management.","volume":"4","author":"Gupta","year":"2012","journal-title":"Front Biosci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib121","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/MJT.0000000000000102","article-title":"Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis","volume":"24","author":"Tabibian","year":"2017","journal-title":"Am. J. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2024.117283_bib122","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00535-015-1064-1","article-title":"The microbiota in inflammatory bowel disease","volume":"50","author":"Sheehan","year":"2015","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.biopha.2024.117283_bib123","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bcp.2018.08.037","article-title":"Gut microbiota, cannabinoid system and neuroimmune interactions: new perspectives in multiple sclerosis","volume":"157","author":"Mestre","year":"2018","journal-title":"Biochem Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2024.117283_bib124","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/er.2017-00192","article-title":"Evaluating causality of gut microbiota in obesity and diabetes in humans","volume":"39","author":"Meijnikman","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.biopha.2024.117283_bib125","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/872632","article-title":"The link between ankylosing spondylitis, Crohn's disease, Klebsiella, and starch consumption","volume":"2013","author":"Rashid","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.biopha.2024.117283_bib126","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fcimb.2019.00044","article-title":"Rifaximin alters intestinal microbiota and prevents progression of ankylosing spondylitis in mice","volume":"9","author":"Yang","year":"2019","journal-title":"Front Cell Infect. Microbiol"},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib127","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12974-021-02303-y","article-title":"Rifaximin-mediated gut microbiota regulation modulates the function of microglia and protects against CUMS-induced depression-like behaviors in adolescent rat","volume":"18","author":"Li","year":"2021","journal-title":"J. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.biopha.2024.117283_bib128","first-page":"Cd011585","article-title":"Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis","volume":"7","author":"Zacharias","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.biopha.2024.117283_bib129","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.biopha.2024.117283_bib130","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.clinthera.2011.06.007","article-title":"Rifaximin: new therapeutic indication and future directions","volume":"33","author":"Rivkin","year":"2011","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.117283_bib131","doi-asserted-by":"crossref","first-page":"92","DOI":"10.15403\/jgld-4871","article-title":"Update on the role of rifaximin in digestive diseases","volume":"32","author":"Dumitrascu","year":"2023","journal-title":"J. Gastrointestin Liver Dis."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224011673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224011673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:40:49Z","timestamp":1777862449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224011673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":131,"alternative-id":["S0753332224011673"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117283","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of rifaximin in liver diseases","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117283"}}